Altai Protocol Library

1023 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara

New Indication: Osimertinib as adjuvant therapy for EGFR-mutated NSCLC

New Indication: Osimertinib as adjuvant therapy for EGFR-mutated NSCLC
Study:
  • Double-blind, phase 3 trial (ADAURA)
  • Completely resected, non-squamous, stage IB, II, or IIIA; EGFR mutation-positive
  • Osimertinib (n=339) vs. placebo (n=343)
Efficacy:
  • DFS @ 2 yrs: 89% vs. 52% (HR: 0.20 [0.14-0.30])
  • CNS-disease free survival @ 2 yrs: 98% vs. 85% (HR: 0.18 [0.10-0.33])
Safety:
  • Grade 3-4 AEs: Diarrhea (2%), stomatitis (2%), paronychia, decreased appetite

N Engl J Med 2020; 383:1711-1723

Yi-Long W, et al. Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

https://doi.org/10.1056/NEJMoa2027071

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More